MA54522A - Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire - Google Patents
Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaireInfo
- Publication number
- MA54522A MA54522A MA054522A MA54522A MA54522A MA 54522 A MA54522 A MA 54522A MA 054522 A MA054522 A MA 054522A MA 54522 A MA54522 A MA 54522A MA 54522 A MA54522 A MA 54522A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pharmaceutical composition
- arterial hypertension
- pulmonary arterial
- pulmonary
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018086724 | 2018-12-21 | ||
| EP2019051830 | 2019-01-25 | ||
| EP2019060151 | 2019-04-18 | ||
| EP2019066494 | 2019-06-21 | ||
| EP2019067186 | 2019-06-27 | ||
| EP19832954.2A EP3897646B1 (fr) | 2018-12-21 | 2019-12-20 | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| PCT/EP2019/086754 WO2020128017A1 (fr) | 2018-12-21 | 2019-12-20 | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54522A true MA54522A (fr) | 2022-03-23 |
| MA54522B1 MA54522B1 (fr) | 2024-07-31 |
Family
ID=69147670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54522A MA54522B1 (fr) | 2018-12-21 | 2019-12-20 | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11234980B2 (fr) |
| EP (1) | EP3897646B1 (fr) |
| JP (2) | JP2022512493A (fr) |
| KR (1) | KR20210109558A (fr) |
| CN (1) | CN113194953A (fr) |
| AU (1) | AU2019410727B2 (fr) |
| BR (1) | BR112021011999A2 (fr) |
| CA (1) | CA3123990A1 (fr) |
| CL (1) | CL2021001636A1 (fr) |
| CO (1) | CO2021007186A2 (fr) |
| DK (1) | DK3897646T3 (fr) |
| ES (1) | ES2983314T3 (fr) |
| FI (1) | FI3897646T3 (fr) |
| HR (1) | HRP20240875T1 (fr) |
| HU (1) | HUE067126T2 (fr) |
| IL (1) | IL284136A (fr) |
| JO (1) | JOP20210153A1 (fr) |
| LT (1) | LT3897646T (fr) |
| MA (1) | MA54522B1 (fr) |
| MX (1) | MX2021007455A (fr) |
| PH (1) | PH12021551371A1 (fr) |
| PL (1) | PL3897646T3 (fr) |
| PT (1) | PT3897646T (fr) |
| RS (1) | RS65689B1 (fr) |
| SG (1) | SG11202105098VA (fr) |
| SI (1) | SI3897646T1 (fr) |
| SM (1) | SMT202400274T1 (fr) |
| TW (1) | TWI841649B (fr) |
| WO (1) | WO2020128017A1 (fr) |
| ZA (1) | ZA202105111B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3658140T (lt) * | 2017-02-27 | 2025-08-25 | Idorsia Pharmaceuticals Ltd | Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui |
| US20210386944A1 (en) * | 2018-10-12 | 2021-12-16 | Sanotize Research Development Corp. | Gas-evolving compositions and container and delivery systems |
| MA54522B1 (fr) | 2018-12-21 | 2024-07-31 | Actelion Pharmaceuticals Ltd | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| TW202042818A (zh) * | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| KR20220106974A (ko) * | 2019-11-29 | 2022-08-01 | 액테리온 파마슈티칼 리미티드 | 폐동맥 고혈압을 치료하는 방법 |
| US20240299384A1 (en) * | 2021-02-26 | 2024-09-12 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0116237B8 (pt) | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
| WO2007031933A2 (fr) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Composition pharmaceutique stable a pyrimidine-sulfamide |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| WO2010018549A2 (fr) * | 2008-08-13 | 2010-02-18 | Actelion Pharmaceuticals Ltd | Compositions thérapeutiques contenant du macitentan |
| JP2019533713A (ja) | 2016-11-10 | 2019-11-21 | アレーナ ファーマシューティカルズ，インク． | ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法 |
| WO2018153925A1 (fr) * | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Compositions pharmaceutiques stables comprenant du macitentan |
| LT3658140T (lt) * | 2017-02-27 | 2025-08-25 | Idorsia Pharmaceuticals Ltd | Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui |
| MA54522B1 (fr) | 2018-12-21 | 2024-07-31 | Actelion Pharmaceuticals Ltd | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
| BR112022010098A2 (pt) | 2019-11-26 | 2022-09-06 | Actelion Pharmaceuticals Ltd | Composição farmacêutica para o tratamento de doença vascular pulmonar e/ou disfunção cardíaca em pacientes submetidos à cirurgia de fontan |
-
2019
- 2019-12-20 MA MA54522A patent/MA54522B1/fr unknown
- 2019-12-20 SI SI201930781T patent/SI3897646T1/sl unknown
- 2019-12-20 CA CA3123990A patent/CA3123990A1/fr active Pending
- 2019-12-20 EP EP19832954.2A patent/EP3897646B1/fr active Active
- 2019-12-20 JO JOP/2021/0153A patent/JOP20210153A1/ar unknown
- 2019-12-20 SG SG11202105098VA patent/SG11202105098VA/en unknown
- 2019-12-20 TW TW108146917A patent/TWI841649B/zh active
- 2019-12-20 KR KR1020217022508A patent/KR20210109558A/ko active Pending
- 2019-12-20 MX MX2021007455A patent/MX2021007455A/es unknown
- 2019-12-20 LT LTEPPCT/EP2019/086754T patent/LT3897646T/lt unknown
- 2019-12-20 PT PT198329542T patent/PT3897646T/pt unknown
- 2019-12-20 HR HRP20240875TT patent/HRP20240875T1/hr unknown
- 2019-12-20 FI FIEP19832954.2T patent/FI3897646T3/fi active
- 2019-12-20 ES ES19832954T patent/ES2983314T3/es active Active
- 2019-12-20 DK DK19832954.2T patent/DK3897646T3/da active
- 2019-12-20 PL PL19832954.2T patent/PL3897646T3/pl unknown
- 2019-12-20 RS RS20240742A patent/RS65689B1/sr unknown
- 2019-12-20 WO PCT/EP2019/086754 patent/WO2020128017A1/fr not_active Ceased
- 2019-12-20 CN CN201980084868.5A patent/CN113194953A/zh active Pending
- 2019-12-20 HU HUE19832954A patent/HUE067126T2/hu unknown
- 2019-12-20 AU AU2019410727A patent/AU2019410727B2/en active Active
- 2019-12-20 JP JP2021533836A patent/JP2022512493A/ja active Pending
- 2019-12-20 SM SM20240274T patent/SMT202400274T1/it unknown
- 2019-12-20 BR BR112021011999-0A patent/BR112021011999A2/pt unknown
-
2021
- 2021-03-02 US US17/189,881 patent/US11234980B2/en active Active
- 2021-05-31 CO CONC2021/0007186A patent/CO2021007186A2/es unknown
- 2021-06-10 PH PH12021551371A patent/PH12021551371A1/en unknown
- 2021-06-17 IL IL284136A patent/IL284136A/en unknown
- 2021-06-18 CL CL2021001636A patent/CL2021001636A1/es unknown
- 2021-07-20 ZA ZA2021/05111A patent/ZA202105111B/en unknown
- 2021-10-29 US US17/515,132 patent/US11464777B2/en active Active
-
2022
- 2022-09-27 US US17/953,530 patent/US20230020241A1/en not_active Abandoned
-
2024
- 2024-05-08 JP JP2024075949A patent/JP2024105450A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3755804A4 (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3496662A4 (fr) | Protéine dérivée de la soie pour le traitement d'une inflammation | |
| EP3946357A4 (fr) | Formulations topiques pour le traitement de neuropathies périphériques | |
| EP3810091A4 (fr) | Méthodes et compositions pour le traitement de l'hypertension pulmonaire | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3716966A4 (fr) | Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| EP3877402A4 (fr) | Traitement combiné pour l'hypertension résistante | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| MA55982A (fr) | Composition pharmaceutique pour le traitement de tumeurs | |
| EP3758716A4 (fr) | Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium | |
| MA55490A (fr) | Mutéine de lipocaline pour le traitement de l'asthme | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP4052694A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire | |
| EP4340881A4 (fr) | Anticorps pour le traitement d'alpha-synucléinopathies | |
| EP3810647A4 (fr) | Méthodes et compositions pour le traitement de l'hémophilie | |
| EP3979817A4 (fr) | Composition pour l'inhibition de transporteur de prostaglandines et applications thérapeutiques associées | |
| EP4230652A4 (fr) | Anticorps anti-oscar pour la prévention ou le traitement de l'arthrose | |
| EP4069278A4 (fr) | Méthodes et compositions pour le traitement et la prévention du diabète de type 1 | |
| MA54809A (fr) | Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique | |
| EP3880244A4 (fr) | Compositions immunogènes pour le traitement de l'hépatite b |